BIOCRYST PHARMACEUTICALS, INC. Effective Income Tax Rate Reconciliation, Other Adjustments, Amount
BIOCRYST PHARMACEUTICALS, INC. (BCRX) reported Effective Income Tax Rate Reconciliation, Other Adjustments, Amount of $4.93 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationOtherAdjustments · last filed 2026-02-26
- BIOCRYST PHARMACEUTICALS, INC. effective income tax rate reconciliation, other adjustments, amount for fiscal 2025 was $4.93M.
- BIOCRYST PHARMACEUTICALS, INC. effective income tax rate reconciliation, other adjustments, amount for fiscal 2024 was -$107.00K, a 121.19% decline from fiscal 2023.
- BIOCRYST PHARMACEUTICALS, INC. effective income tax rate reconciliation, other adjustments, amount for fiscal 2023 was $505.00K.
- BIOCRYST PHARMACEUTICALS, INC. effective income tax rate reconciliation, other adjustments, amount for fiscal 2022 was -$5.49M, a 551.07% decline from fiscal 2021.
| Period end | Effective Income Tax Rate Reconciliation, Other Adjustments, Amount 12 month | Effective Income Tax Rate Reconciliation, Other Adjustments, Amount 12 month as first filed |
|---|---|---|
| 2025-12-31 | $4.93M 10-K · filed 2026-02-26 | |
| 2024-12-31 | -$107.00K 10-K · filed 2026-02-26 | $2.50M 10-K · filed 2025-02-25 |
| 2023-12-31 | $505.00K 10-K · filed 2026-02-26 | $1.66M 10-K · filed 2024-02-27 |
| 2022-12-31 | -$5.49M 10-K · filed 2025-02-25 | |
| 2021-12-31 | $1.22M 10-K · filed 2024-02-27 | |
| 2020-12-31 | $1.46M 10-K · filed 2023-02-27 | |
| 2019-12-31 | $281.00K 10-K · filed 2022-02-28 | |
| 2018-12-31 | $18.00K 10-K · filed 2021-03-01 | |
| 2017-12-31 | $1.64M 10-K · filed 2020-03-13 | |
| 2016-12-31 | $822.00K 10-K · filed 2019-03-14 | |
| 2015-12-31 | -$218.00K 10-K · filed 2018-03-12 | |
| 2014-12-31 | -$115.00K 10-K · filed 2017-02-27 | |
| 2013-12-31 | $1.14M 10-K · filed 2016-02-26 | |
| 2012-12-31 | $281.00K 10-K · filed 2015-03-02 | |
| 2011-12-31 | $731.00K 10-K · filed 2014-03-10 | |
| 2010-12-31 | $253.00K 10-K · filed 2013-03-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |